The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
A Novel Ovarian Xenografting Model to Characterize the Impact of Chemotherapy Agents on Human Primordial Follicle Reserve
Open accessAbstract
Many chemotherapeutic agents, especially of the alkylating family, alter fertility in premenopausal females. However, it is not practically possible to quantify and characterize the impact of cancer drugs on ovarian reserve in a clinical setting. Thus, our specific aim was to develop a xenograft model to characterize the in vivo impact of chemotherapy agents on human ovary. Ovarian pieces from 24 weeks old abortuses were xenografted s.c. to severe combined immunodeficient mice (n = 52). Animals received either a single dose of 200 mg/kg of cyclophosphamide or the vehicle. Grafts were recovered from the control and treated mice 12 to 72 h after the cyclophosphamide injection and serially sectioned for primordial follicle counts. Apoptosis was assessed with terminal nucleotidyl transferase–mediated nick end labeling (TUNEL) assay. Platelet/endothelial cell adhesion molecule 1 (PECAM-1) staining, as well as intra-vital fluorescein-conjugated lectin and Evans blue labeling were done to assess microvasculature by confocal microscopy. Although there was 12% reduction in primordial follicle density by 12 h following treatment (P > 0.05), the follicle loss increased significantly at 24 h (53%, P < 0.01) and peaked at 48 h (93%, P < 0.0001). TUNEL staining peaked at 12 h, earlier than the diminishment in follicle numbers, and decreased thereafter. Xenograft vascularization pattern was similar to non-xenografted tissue, indicating appropriate in vivo drug delivery. The impact of cyclophosphamide on primordial follicle reserve in our human ovarian xenograft model is consistent with the clinical gonadotoxicity of this drug. Human ovarian xenografting is a promising model to characterize the gonadotoxic effects of current and emerging cancer drugs without a need for lengthy clinical studies. [Cancer Res 2007;67(21):10159–62]
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., & Thun, M. J. (2007) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.57.1.43 · Cited by 7,439
Kelland, L. R. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2003.11.028 · Cited by 352
Cited by
Kalich-Philosoph, L., Roness, H., Carmely, A., Fishel-Bartal, M., Ligumsky, H., Paglin, S., Wolf, I., Kanety, H., Sredni, B., & Meirow, D. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005402 · Cited by 542
How do chemotherapeutic agents damage the ovary?
Morgan, S., Anderson, R. A., Gourley, C., Wallace, W. H., & Spears, N. (2012) · Human Reproduction Update · doi:10.1093/humupd/dms022 · Cited by 409
Chemotherapy-Induced Damage to Ovary: Mechanisms and Clinical Impact
Bedoschi, G., Navarro, P. A., & Oktay, K. (2016) · Future Oncology · doi:10.2217/fon-2016-0176 · Cited by 356
Self-citationGerber, B., von Minckwitz, G., Stehle, H., Reimer, T., Felberbaum, R., Maass, N., Fischer, D., Sommer, H. L., Conrad, B., Ortmann, O., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.5704 · Cited by 297
Oktem, O., & Oktay, K. (2007) · Cancer · doi:10.1002/cncr.23071 · Cited by 289
Self-citation
Metadata
- Authors
- Oktem, O., & Oktay, K.
- Venue
- Cancer Research
- Published
- 2007-11-01
- Volume
- 67
- Issue
- 21
- Pages
- 10159-10162
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2167555656
- Cited by
- 212
- References
- 2
- FWCI
- 8.64
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Novel Ovarian Xenografting Model to Characterize the Impact of Chemotherapy Agents on Human Primordial Follicle Reserve. https://app.cochat.ai/papers/10.1158/0008-5472.can-07-2042
- The paper
- Oktem, O., & Oktay, K. (2007). A Novel Ovarian Xenografting Model to Characterize the Impact of Chemotherapy Agents on Human Primordial Follicle Reserve. Cancer Research. https://doi.org/10.1158/0008-5472.can-07-2042
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.